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Abstract  
 
Background: Kratom (Mitragyna speciosa) use has increased in Western countries, with a growing 
number of associated deaths. There is a growing debate about the involvement of kratom in these 
events. 
 
Aims: This study details characteristics of such fatalities and provides a ‘state-of-the-art’ review.   
 
Methods: UK cases were identified from mortality registers by searching with the terms: ‘kratom’, 
‘mitragynine’, etc. Databases and online media were searched using these terms and ‘death’, ‘fatal*’, 
‘overdose’, ‘poisoning’, etc. to identify additional cases; details were obtained from relevant officials. 
Case characteristics were extracted into an Excel spreadsheet, and analysed employing descriptive 
statistics and thematic analysis.   
 
Results: Typical case characteristics (n=156): male (80%); mean age 32.3 years; White (100%); drug 
abuse history (95%); reasons for use - self-medication, recreation, relaxation, body-building, avoiding 
positive drug tests. Mitragynine alone was identified/implicated in 23% of cases. Polysubstance use 
was common (87%), typically controlled/recreational drugs; therapeutic drugs; alcohol. Death 
cause(s) included: toxic effects of kratom ± other substances; underlying health issues. 
 
Conclusions: These findings add substantially to the knowledge-base on kratom-associated deaths; 
these need systematic, accurate recording. Kratom’s safety profile remains only partially understood; 
toxic and fatal levels require quantification.  
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1. Introduction 
 
Kratom (Mitragyna speciosa Korth) is a tree native to South-East Asia (especially Malaysia, Thailand 
and Indonesia), New Guinea and the Philippines. It typically grows to between 4 and 16 metres in 
height. (Mis)use of kratom appears to have increased in Western countries over the past decade, with 
a growing number of deaths (reviewed below) being reported as associated with this plant and 
synthetic forms of its active ingredients mitragynine and 7-Hydroxymitrgynine (Figures 1 and 2). Some 
context is provided, through means of a ‘state-of-the-art’ review (Grant and Booth, 2009), against 
which these deaths can be understood. This paper present outlines the principal characteristics of 
decedents and fatalities related to kratom use. Furthermore, it discusses the implications of the way in 
which these cases are identified, reported, recorded and interpreted.   
 
< Figures 1 and 2 about here > 
 
2. Overview of the state of knowledge of Kratom 
 
2.1. Chemistry and pharmacology 
 
Amongst the psychoactive ingredients found in kratom leaves are the alkaloids mitragynine and its 
main metabolite 7-hydroxymitragynine. Mitragynine was first isolated in Edinburgh in 1921 (Chemist & 
Druggist, 1930). These molecules bind to the µ (mu), κ (kappa) and δ (delta) opioid receptors (Holler 
et al., 2011; Prozialec et al., 2012), acting as an agonist at all three receptors, and antagonist at the δ 
receptor (Kruegel et al., 2016; Váradi et al., 2016). An in vivo mice study demonstrated that 
mitragynine acts as an antagonist on the serotonin and noradrenaline receptor systems (Matsumoto 
et al., 1996). 
 
It is reported that 7-hydroxymitragynine has a potency 13-times higher than morphine (Takayama, 
2004) and 46-times that of mitragynine (Matsumoto et al., 2004; Shellard et al., 1978). Kratom’s 
pharmacological properties are affected by where, when and how it is cultivated. Plants from 
Indonesia contain higher levels of mitragynine and related alkaloids than those from Malaysia and 
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Thailand (Orio et al., 2012). Kratom varieties with red-veined leaves (only found in Thailand) are 
reported to be more sedating than those with green or white leaves which are more stimulating, 
according to drug user fora (Domingo et al., 2017).  
 
The approximate mitragynine content of fresh kratom leaves is 0.86 mass % compared to 0.026 
mass% for 7-hydroxymitragynine (Ponglux et al., 1994). Levels in kratom products are in the range of 
about 1.5 - 2 mass % and about 0.02 - 0.33 mass % respectively for these substances (Kikura-
Hanajiri et al., 2009; Lydecker et al., 2016). So, the concentration of mitragynine is 50 - 100 times that 
of its hydroxy metabolite (Kruegel and Grundmann, 2018). 
 
A typical dose of 8 g of raw kratom may mean that a 70 kg individual is exposed to 120 – 180 mg of 
mitragynine and 1.1 - 3.4 mg of 7-hydroxymitragynine (1.2 - 2.5 mg/kg and 0.015 - 0.048 mg/kg 
respectively) (Kruegel and Grundmann, 2018). Full effects are usually apparent 30 - 60 min after oral 
consumption but onset may be felt within 10 - 20 min. Kratom’s effects can last 5 - 7 h, being 
strongest 2 - 4 h after ingestion; weak effects can be felt up to a day later (Maruyama et al., 2009; 
Prozialeck et al., 2012; Rosenbaum et al., 2012; Scott et al., 2014). 
 
2.2. Metabolism and pharmacokinetics 
 
There appears to be few human studies of mitragynine and 7-hydroxymitragynine pharmacokinetics. 
Trakulsrichai et al. (2015) suggest a two-compartment model of metabolism for mitragynine. Following 
oral consumption, the half-lives of mitragynine and 7-hydroxymitragynine are about 3.5 and 2.5 h 
respectively (Henningfield et al., 2018). Both are eliminated primarily in urine (Neerman et al., 2013; 
Prozialeck et al., 2012). Absolute bioavailability is about 3% for mitragynine (Parthasarathy et al., 
2010). However, this would not appear to be explained by either a high first-pass metabolism or poor 
gastro-intestinal absorption (Kruegel and Grundmann, 2018). Blood levels of mitragynine of up to 191 
ng/mL after consumption of tea containing 104, 166 and 192 g/mL of kratom over 7 days were 
recorded in 10 chronic kratom users (Trakulsrichai et al., 2015). LD50 levels for mitragynine in rodent 
studies have been reported as 200 mg/kg in a rat (Janachawee et al., 2007) and mice at 477 mg/kg 
(Sabetghadam et al., 2013). It appears that the LD50 levels for Swiss Webster male rats is similar for 
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intra-venous (IV) Mitragynine (27.8 mg/kg), 7-Hydroxymitragynine (24.7 mg/kg), and heroin (23.7 
mg/kg), whereas the LD50 level for oral Mitragynine in the same animals is 547.7 mg/kg (Smith et al., 
2019). 
 
2.3. Availability, routes of administration and usage 
 
Mitragynine is insoluble in water but can be dissolved using a range of conventional organic solvents 
such as acetic acid, acetone, chloroform, diethyl ether and alcohols (EMCDDA, 2015a). The dried 
leaves can also be consumed as a tea or smoked (Hassan et al., 2013). According to consumers, the 
amount of leaves that constitutes a typical dose cannot easily be smoked (Cinosi et al., 2015). 
Products derived from kratom are typically found as crushed or powdered leaves. Some powder 
preparations, green or beige-brown in colour, have additional leaf extracts added. Paste-like extracts 
and dark brown resin can be prepared by boiling off the water from aqueous leaf suspensions. These 
can be added to finely chopped palm leaves and made into pills or smoked in pipes as “madatin” 
(Azizi et al., 2013). Alternatively, extracts can be added to hot water and then consumed alone or 
added to herbal teas to make it more acceptable - “toss and wash” (Cinosi et al., 2015; Hanapi et al., 
2013). Small pellets, capsules or paper ‘bombs’ filled with kratom powder are also available for oral 
ingestion. In the USA the most popular modes of consumption are powdered form with a beverage, 
pill, pure powder or as a tea (Grundmann, 2017). Other users prefer to take kratom with food, making 
cookies or mixing it with yoghurt to counteract its bitter taste (Cinosi et al., 2015). More recently, 
evidence has emerged of intravenous injecting of kratom (Lydecker et al., 2017). Kratom extracts 
(tinctures) are now available for use in vapourisers (Abayarathna and Jaehne, 2016; Poklis et al., 
2017). 
 
Tinctures and drinks, including alcohol and/or other psychoactive substances, can be purchased. 
Common additions in South-East Asia are cough syrups containing codeine or diphenhydramine to 
which are added a caffeine-based soft drink, and an anti-depressant, an anxiolytic or an analgesic 
(EMCDDA, 2015a; Tungtananuwat and Lawanprasert, 2010): an example in Thailand and Malaysia is 
the “4 x 100” cocktail (Tanguay, 2011; Tungtananuwat and Lawanprasert, 2010), which is believed to 
have more intoxicating effects (Chongrathanakon et al., 2017). In other contexts and/or regions a 
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variety of both ‘traditional’ recreational substances (e.g. alcohol, amphetamines, benzodiazepines, 
cannabis, cocaine, hallucinogens, methadone and paracetamol) and new/novel psychoactive 
substances (NPS) such as kava, synthetic cathinones, phenethylamines and tryptamines are also 
taken with kratom products/ingredients (Anwar et al., 2016; Cinosi et al., 2015).  
 
As with other ‘herbal’ products, consumers of kratom or related derivatives, whether purchasing online 
or from other outlets, need to be aware that there is not only variability in the concentrations of 
kratom, but there is also the potential for such products to contain very dangerous/potent ingredients 
such as O-desmethyltramadol (Scott et al., 2014). However, Griffin et al. (2016) found that products 
marketed as liquid pain relief and containing mitragynine did contain kratom. Nevertheless, it is worth 
noting that the concentrations of 7-hydroxymitragynine found in products may be artificially made 
considerably higher than those found in kratom leaves (Lydecker et al., 2016). 
 
There appears to be a dose-response effect: 1 - 5 g of leaves (low to moderate doses) generate mild 
stimulant effects that enable workers to stave off fatigue in Thailand and other South-East Asia 
regions (Cinosi et al., 2015; Prozialec et al., 2012), as well as recreational effects such as a 
perception of being more 'alert', “entactogenic” effects like empathy and euphoria, sometimes sexual 
arousal is increased (Cinosi et al., 2015); 5 - 15 g (moderate to high doses) produce opioid-like 
effects, and have been employed to not only manage pain, diarrhoea, and opioid withdrawal 
symptoms but also for euphoriant effects; over 15 g (very high doses) often give rise to sedative 
effects, inducing intoxication (Prozialec et al., 2012), and causing opioid-like analgesic effects, as well 
as causing users to be “less sensitive to physical or emotional pain, to feel and look calm, and to have 
a general feeling of comfortable pleasure... Others report an increase of empathy feelings” (Cinosi et 
al., 2015). Boyer et al. (2008) note that as early as the 1830s kratom was reported as being used as a 
substitute for opiates. 
 
2.4. Addiction potential 
 
There are case-reports of chronic kratom use leading to tolerance, cross-tolerance to both kratom and 
opiates, physical dependence/addiction, craving and withdrawal problems from South-East Asia, 
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Europe and the USA (Adkins et al., 2011; Assanangkornchai et al., 2007; Babu et al., 2008; Boyer et 
al., 2008; Cinosi et al., 2015; McWhirter and Morris, 2016; Roche et al., 2008; Saingam et al., 2013; 
Suwanlert, 1975). Whilst some users report low craving, others experience difficulty in abstaining 
(Ahmad and Aziz, 2012; Singh et al., 2015). Kratom tolerance develops slower than for morphine and 
has lower potential for addiction (Váradi et al., 2016). As with opioids, neonatal abstinence syndrome 
has been described in some cases (Davidson et al., 2019; Eldridge et al., 2018; Mackay and 
Abraham, 2018; Murthy and Clark, 2019; Trakulsrichai et al., 2013). The addiction potential of kratom 
and its main alkaloids is still controversial in the scientific community and on discussion websites 
(Hassan et al., 2012), but mitragynine probably merits further investigation in respect of its potential 
for use in opioid dependence (Yue et al., 2018) and chronic pain relief. It may be that mitragynine 
rather than 7-Hydroxymitragynine is more suited for such uses (Hemby et al., 2018) because of the 
former’s lower abuse potential. 
 
Withdrawal symptoms are similar to those described for traditional opioids but are milder  
(Singh et al., 2014, 2016) and overlap in terms of side-effects, including: decreased appetite, 
anorexia, weight loss, decreased sexual drive, insomnia, myalgia (muscle spasms and pain), 
arthralgia (aching in the muscles and bones), jerky movement of the limbs, watery eyes/nose, 
rhinorrhoea, dry mouth, hot flushes, hypertension, fever, nausea, frequent micturition, and diarrhoea 
(Burkill and Haniff, 1930; Cinosi et al., 2015; Hassan et al., 2012; Singh et al., 2014; Stanciu et al., 
2019). Most of these effects appear to be dose-dependent (Grundmann, 2017; Smith and Lawson, 
2017). Psychological withdrawal symptoms commonly reported are: dysphoria, nervousness, 
restlessness, tension, anger, hostility, irritability, aggression, and sadness (Singh et al., 2014; 
Suwanlert, 1975). Psychotic symptoms such as mental confusion, delusion, and hallucination are 
reportedly caused by regular use of kratom (Suwanlert, 1975). On the other hand, a recent small-
scale study appears to show that long-term use by regular kratom users does not impair motor, 
memory, attention or executive function (Singh et al., 2019). One recent US study reported that about 
two-fifths (42.6%) of users reported some form of withdrawal symptom (Grundmann, 2017). 
 
2.5. Adverse effects of using  
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Common side-effects reported include: decreased appetite, anorexia, weight loss, temporary erectile 
dysfunction, insomnia, sweating, hyperpigmentation, hair loss, and tremor, and constipation (Cinosi et 
al., 2015). The commonest symptoms reported in the USA are: tachycardia (25.0%); 
agitation/irritability (23.8%); drowsiness (19.4%); nausea (14.7%); and hypertension (11.7%) (Anwar 
et al., 2016). These symptoms, together with anxiety, are reported by other researchers (Prozialeck et 
al., 2012; Singh et al., 2014; Swogger et al., 2015). Kratom appears capable of raising prolactin levels 
leading to secondary hypogonadism (LaBryer et al., 2018). Chronic use can also cause elevated 
levels of transaminases (Carter et al., 2016).  
 
Reported adverse effects, following high doses and/or the use of concentrated extracts, include: 
tachycardia (Lu et al., 2014); intrahepatic cholestasis (Griffiths et al., 2018; Kapp et al., 2011; Riverso 
et al., 2018), hepatitis (including cholestatic) and liver toxicity (Dorman et al., 2015; Drago et al., 2017; 
Forrester, 2013; Kupferschmidt, 2011); seizure and coma (Nelsen et al., 2010; Pantano et al., 2016; 
Roche et al., 2008); Adult Respiratory Distress Syndrome (Jaliawalia et al., 2018; Pathak et al., 2014); 
and hypothyroidism (Sheleg and Collins, 2011). Repeated kratom use can lead to generalised tonic 
clonic seizures and possible structural brain lesions and symptomatic focal epilepsy (Tatum et al., 
2018). Cerebral haemorrhage following the use of kratom by an intravenous heroin user in remission 
has been reported (Liss et al., 2016). 
 
2.6. Epidemiology 
 
Information on the epidemiology of kratom use is scarce, due, in part, to the absence of robust 
metrics on typical doses, regularity of use, etc. Most information on kratom prevalence relates to its 
use in Thailand where it is used as a self-medicating substance to treat opiate/opioid dependence, 
and as an opium substitute in Malaysia (Ahmad and Aziz, 2012). In 2012, some 1.23 million 
individuals in Thailand reported lifetime use (ASCAN, 2012), with 76,990 having taken a “kratom 
cocktail”. A national survey in 2016 found lifetime use of kratom leaves at 15.1% compared to 14.5% 
for the cocktail; last year use was 2.1% and 0.7% respectively (Wonguppa and Kanato, 2017). The 
consumption of the cocktail appears to have been causing concern in official circles for several years, 
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especially in the Thailand/Malaysia border regions (Chang Rai Times, 2018). Facebook pages in Thai 
are typically positive and neutral towards kratom rather than negative in tone (Thaikla et al., 2018).  
 
Misuse of kratom has increased in Western countries in years. Internet surveys conducted by the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in 2008 indicated that kratom 
was one of the most widely offered ‘legal highs’ in 44% of the 27 European online shops investigated 
(Hillebrand et al., 2010). A more extensive EMCDDA Internet survey in July 2011 showed that kratom 
was the most widely offered product with 128 out of 631 (20%) of online retailers shipping it to the EU 
(EMCDDA, 2011). An Internet snapshot carried out in the UK in April 2009 showed that among the 
346 unique products offered by 39 shops, kratom (n=30) was second only to Salvia divinorum 
(Schmidt et al., 2011). Kratom products can be bought from ‘head’, ‘smart’ and ‘herbal’ shops and 
increasingly online from overseas (Cinosi et al., 2015). The latter sources are likely to be based in 
Indonesia, e.g. ‘Bali Kratom’ where it is not controlled. The Internet is being increasingly used as a 
means of sourcing kratom for those using it for self-medication purposes (Boyer et al., 2008; Cinosi et 
al., 2015; EMCDDA, 2015a). The principal reasons for this self-medication are (a) to manage opioid 
withdrawal by individuals with chronic pain; (b) to alleviate symptoms associated with withdrawal from 
heroin, methadone and suboxone; and (c) for its ability to treat depression and anxiety. 
 
Kratom use appears to be increasing in the United States (Warner et al., 2016), especially for self-
management of opioid withdrawal and pain relief (Grundmann, 2017; Prozialeck, 2016). Pain relief 
appears to be the most common reason, closely followed by emotional/mental conditions such as 
anxiety, depression and Post Traumatic Stress Disorder (PTSD), followed by drug dependency 
(Grundmann, 2017). This increase appears to be reflected in the number of calls to the US National 
Poison Data System database. The number of calls rose from 26 in 2010 to 263 in 2015 (Anwar et al., 
2016). The median age of cases was 28 years (range 2 months - 69 years); 71.7% were male. 
Between 2011 and 2017 about 1800 kratom exposures had been reported nationally, with two-thirds 
of these being during 2016-2017 (Post et al., 2019). By contrast, the Malaysian National Poison 
Center recorded only two cases of mitragynine poisonings between 2006 and 2009 (Daud et al., 
2012). Forensic toxicology investigations in cases involving NPS in the USA also indicate an 
increasing proportion being attributed to mitragynine. For example, one laboratory (NMS) reports the 
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proportion of its NPS Blood Positive Confirmations where mitragynine was identified rising from 4.7% 
in 2013, to 12% in 2014, and to 15.48% in the first six months of 2016; being the second most 
frequently identified NPS during the latter period (Logan, 2016a, 2016b).  
 
A survey of in-patient substance users conducted in the USA during April 2017 found that 10% had 
used kratom in the previous 12 months and such individuals were more likely to attend Emergency 
Departments (EDs), and to use it as a replacement for heroin (64%), because of a disability or chronic 
pain (18%). Some 43% used it because of curiosity and a similar proportion to bypass drug tests 
(Smith and Lawson, 2017). Commonly used drug screening methods do not detect kratom and its 
metabolites, and this may be another reason for its spreading use, to avoid positive opioid results in 
occupational or detoxification drug testing (Fuenffinger et al., 2017; Gunderson et al., 2014; Lesiak et 
al., 2014; Perrone et al., 2013; Prutipanlai et al., 2017; Warner et al., 2016). 
 
2.7. Legal status of Kratom 
 
The kratom plant, but moreover mitragynine and its other metabolites, do not appear in any of the 
United Nations’ Drug Conventions schedules. Kratom itself is regarded by the United Nations Office 
for Drugs and Crime (UNODC) and the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) as an NPS (EMCDDA, 2015b; UNODC, 2014). However, it is controlled in Australia, 
Malaysia, Myanmar, New Zealand, Russia, South Korea, Thailand (but see below), Vietnam and in 
some US states. The US Food and Drug Administration (FDA) has not approved kratom. The Drug 
Enforcement Agency (DEA) became so concerned about the use of kratom in the USA that on 30 
August 2016 it announced it was going to place it in Schedule I of the Controlled Substances Act 
1970. However, there was such an adverse reception to this news by suppliers, consumers and 
politicians that on 20 October 2016 the DEA withdrew the proposal and extended a public 
consultation process to 1 December 2016 (Henningfield et al., 2018) – see Discussion. In October 
2017, the FDA decided to look separately at Mitragynine and 7-Hydroxymitragynine (Brodwin, 2018), 
and has apparently recommended that both be controlled or regulated (Swetlitz, 2018). At the time of 
writing (February 2019), it is being reported that the Department of Health and Human Services has 
also recommended a ban on the chemicals to the DEA (Swetlitz, 2018). In Canada, kratom-containing 
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products are not authorised for sale (Wang and Walker, 2018). In Thailand the National Legislative 
Assembly completed its approval of a draft bill on 25 December 2018 that amends the country’s 
Narcotic Act 1979; it came into force the day after its publication in the Government Gazette on 18 
February 2019 (LawPlus Ltd, 2019). The new regulations (Narcotics Act (No. 7) B.E. 2562 (A.D. 
2019)) allow the use of cannabis and kratom for government and medical benefits, the treatment of 
patients, research and development, agriculture, commerce, science and industry (Sattaburuth, 
2018). 
 
The amount of kratom seized globally in 2016 was in excess of 400 tons; this was seven times more 
than in the previous year (UNODC, 2018). Most was confiscated in Malaysia (399,139 tons), followed 
by Thailand (5,681 tons), Myanmar (1,413 tons), and Belgium (1 ton). 
 
At the time of writing, kratom, mitragynine and 7-Hydroxymitragynine are controlled in 10 EU Member 
States and Turkey. In the UK, kratom, and its psychoactive metabolites, is regarded by the Medicines 
and Healthcare products Regulatory Agency (MHRA) as a medicinal herb and would require a 
marketing authorisation for sale as a medical treatment (personal communication to lead author from 
MHRA, 17 May 2018). This means it is exempted from regulation under the Psychoactive Substances 
Act 2016, if being used by “healthcare professionals acting in the course of their duty” or employed in 
approved scientific research. But, if kratom is being provided purely for its psychoactive properties 
prosecutions could be sought. If doctors prescribe unlicensed medicines, they need to satisfy 
themselves that there is sufficient safety evidence for the medicines in question. Prior to the 
Psychoactive Substances Act coming into force, the UK Government Chemist advised that kratom 
could not be considered a ‘novel food’ as defined in Regulation (EU) 2015/2283 (LGC, 2018). The 
opioid O-desmethyltramadol, which is more potent than its parent drug tramadol, was added to 
kratom preparations sold as ‘Krypton’. This product resulted in a number of deaths (Bäckstrom et al., 
2010; Kronstrand et al., 2011). As a result, O-desmethyltramadol became controlled in the UK as a 
Class B drug on 26 February 2013.  
 
2.8. Deaths associated with Kratom use 
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Deaths associated with kratom use have been reported. Typically, the decedents had confounding 
health conditions and/or used other substances, whether medicines, traditional stimulants or NPS, or 
indeed combinations thereof. For example: propylhexedrine (Holler et al., 2011); loperamide (Bishop-
Freeman et al., 2016); dextromethorphan, diphenhydramine, temazepam, clonazepam, zopiclone, 
citalopram, and lamotrigine (Neerman et al., 2013); venlafaxine, diphenhydramine and mirtazapine 
(McIntyre et al., 2015); lorazepam, triazolam, fluoxetine, quetiapine, olanzapine, pregabalin, 
pipamperon together with two NPS (a ‘designer benzodiazepine’ - etizolam, and a synthetic cathinone 
- probably 2-MMC) (Domingo et al., 2017); codeine, heroin, paracetamol, amphetamine, 
methamphetamine, MDA, MDMA and pseudoephedrine (Domingo et al., 2017); quetiapine (Hughes, 
2019).   
 
2.9. Aims of the paper 
 
The aims of this paper are to examine the nature of deaths reported associated with the use of 
kratom, to profile decedents, and contribute to the literature concerning mitragynine levels in fatal 
cases, whether as a direct or contributory cause (Domingo et al., 2017). The purpose of doing so is to 
develop the existing limited knowledge-base, so as to inform policy-makers, potential and actual 
users, as well as those who may have to treat them or investigate their deaths. 
 
 
3. Methods 
 
3.1. Data sources and sources for UK fatalities 
 
In the UK context, general mortality registers (GMRs) are part of the national agencies responsible for 
collecting and analysing vital events (births, deaths, marriages and civil partnerships). This study 
draws on information provided by the UK GMRs as part of two EU-funded projects.  
 
The National Programme on Substance Abuse Deaths (NPSAD) is a special mortality register which 
regularly receives information from Coroners on a voluntary basis on deaths related to drugs in both 
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addicts and non-addicts in England, Wales, Northern Ireland, the Channel Islands and the Isle of 
Man. From 2004 to 2011, information was also received from the Scottish Crime and Drug 
Enforcement Agency. Since 1997 details of more than 35,000 deaths have been received. To be 
recorded in the NPSAD database as a drug-related death, at least one of the following criteria must 
be met: (a) presence of one or more psychoactive substances directly implicated in death; (b) history 
of dependence or abuse of drugs; and (c) presence of controlled drugs at post-mortem. Ethical 
approval is not required in the UK for studies whose subjects are deceased and solely involves 
retrospective reviews of death records.  
 
A retrospective study design was employed to identify relevant cases associated with the use of 
kratom. Relevant cases in the UK were identified from both general and specialist mortality registers 
by searching the cause of death fields and post-mortem toxicological data (Scotland, Northern 
Ireland, NPSAD) with the following terms: ‘kratom’, ‘mitragyna’, ‘mitragynine’, ‘7-Hydroxymitragynine’, 
‘O-desmethyltramadol’ and ‘Krypton’. The additional fields searched on the NPSAD database were 
those holding data on - verdict, accident details, and 'other relevant information'. Where cases were 
identified in the UK using the methods detailed in the next paragraph, further details were requested 
and obtained from the relevant pathologists, Coroners and Procurator Fiscals. 
 
3.2. Data sources and sources for non-UK fatalities 
 
In addition, regular searches were undertaken in English of literature databases and search engines 
(Google Scholar, PubMed), ‘grey literature’, and online media sources in Google using the above 
terms in conjunction with the terms ‘death’, ‘fatality’, ‘mortality’, ‘Coroner’, ‘inquest’, ‘conference’, and 
‘abstract’ to identify other cases. Google Scholar alerts were also set up using these terms. Where 
cases outside the UK were identified, contact with those reporting the cases (e.g. media reporters, 
lobby/interest groups) was made by the lead author to obtain further details. Through this process, 
contact was made with the US co-author who had used similar methods, including freedom of 
information requests, to obtain copies of coroner/medical examiner reports, including autopsy reports. 
Some cases were already known to the authors. The sources used for identifying each case are given 
in the relevant tables.  
14 
 
 
3.3. Data extraction and analyses 
 
Key characteristics of such incidents and decedents were extracted from all available sources, with a 
key emphasis on accessing the official documents where possible. These details were entered into a 
Microsoft Office Excel spreadsheet. Characteristics of decedents are examined in terms of age, 
gender, ethnicity, history of drug use, employment, and living arrangements. Characteristics of deaths 
are examined in respect of place of death, number and combinations of post-mortem drugs, role of 
substances in death, manner and cause(s) of death.  
 
Data analysis were performed using Microsoft Office Excel 2016, employing descriptive statistics for 
quantitative information. Data on blood, urine and other tissue (e.g. vitreous humour) concentrations 
are presented, where available. Qualitative information was undertaken using a content/thematic 
analysis approach. 
 
 
4. Results 
 
This study reports on a total of 156 deaths associated with the use of kratom. So far as the authors 
are aware, this is the largest number of cases reported on to date in the literature. Details of these 
individual cases are given in the supplementary spreadsheet (available online). 
 
A total of ten UK deaths have been identified at the time of writing (February 2019) via the methods 
outlined in Section 3.1 above; eight in England and two in Scotland. There have been no known 
deaths involving kratom or its derivatives in Northern Ireland or Wales.  
 
Non-UK cases (n = 146) identified can be broken down into four categories (a) published academic 
papers/abstracts; (b) government reports; (c) media reports; and (d) reports of post-mortem toxicology 
casework.  
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The first group covering case-reports of 40 deaths comprises, in order of publication year: 
Tungtanauwatt and Lawanprasert (2010); Holler et al. (2011); Kronstand et al. (2011); Frost et al. 
(2012); Neerman et al. (2013); Anderson et al. (2014); Karinen et al. (2014); McIntyre et al. (2015); 
Bishop-Freeman et al., 2017; Domingo et al. (2017) (Personal communication, Olwen Domingo, 
University of Munich, 11 April 2017 to lead author); Ramoo et al., 2017; Fogarty et al., 2018; Wang 
and Walker, 2018; Hughes, 2019; Gershman et al., 2019 (Personal communication, Andrew Monte, 
University of Colorado, 28 January 2019 to lead author).  
 
The second group comprises: the US Drug Enforcement Agency (DEA) gives details of 9 US cases 
(DEA, 2016b:23-26). The FDA (2018a, 2018b, 2018c) provides information on 44 deaths, many of 
which are included in the first group above. 
 
The third group, media reports, in date order cover 1 Swedish case  - Petersson (2010) - case 2 
detailed in Kronstand et al. (2011); 1 Irish case - O’Halloran (2011); and numerous cases in the USA, 
e.g. Lystra (2013); Vigil (2014); (Personal communication 30 June 2016 Amy Martin, Chief Medical 
Examiner, Denver, Colorado to lead author); CBS Miami (2014); Whigham (2014a,2014b); 
thewatershed.com (2014); Greenfield (2015); Bruno (2016); Bhattacharjee (2016); McBride (2016); 
Davis (2018); Dunn and Lindstrom (2018); Main (2018); Perno (2018); Smith (2018); Vlahos (2018); 
Wing (2018a, 2018b); one of the US media reports (Vigil, 2014) covers a case cited by the DEA 
(2016b). In addition, post-mortem toxicology results have been published by Brower et al. (2015).  
 
According to the Associate Medical Examiner in Arkansas, kratom was linked to three deaths of 
known kratom users in the state during 2015. In two cases kratom and other controlled substances 
were found in the decedents’ blood. In the third case, involving a healthy male, only kratom was found 
in his system, the probable cause of death being ruled as kratom toxicity (Wooten, 2016). The North 
Carolina Medical Examiner’s Office stated that 23 individuals had died with kratom in their system, 
and for five it was the primary cause of death; although the period covered is unknown (Toler, 2016). 
In addition, mitragynine was also found in 11 post-mortem cases examined in North Carolina (Brower 
et al., 2015). Recently, it was reported that kratom was found in the bodies of at least 27 decedents in 
the last 3 years in the ten most populated counties in the state of Colorado; of these, kratom was 
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considered as contributing to 17 overdoses, and in at least six cases it was the only drug that 
contributed to death (Haarer, 2018). 
 
4.4. Trends and demographic characteristics 
 
Apart from a single case reported from Thailand, all cases reported here occurred in North-Western 
Europe or North America, principally the USA (Table 1). The first documented death occurred in 2008. 
The number of cases appears to have had a peak in 2009-10 (mainly due to nine Krypton cases in 
Sweden), and from 2013 onward there has been a steady increase in cases being reported. The 
majority (80.1%) of victims were male. The mean age was 32.3 (range 17-64) years and, where 
known, all the decedents were White/Caucasian. Where known, most decedents were employed 
(66.7%), and lived with someone else (77.3%).  
 
 
< Table 1 about here > 
 
 
The reasons for using kratom were not available in all cases. However, a range of reasons were 
noted; the main one being self-medication, including for opiate/opioid addiction and anxiety/stress. 
Recreational use and body-building were also mentioned, as was using kratom to avoid positive drug 
tests. In the majority (95.3%) of cases it was known that the decedents had a history of drug abuse, 
including past or current use of Kratom or Krypton (31.4%). 
 
4.5. Characteristics of deaths 
 
About two-thirds (66.1%) of deaths occurred at an individual’s home or that of a family member or 
friend, but 15.2% died in hospital or medical centre. 
 
Tables 2a and 2b present information on the mitragynine and 7-hydroxymitragynine levels given in all 
published fatalities and those covered in this study. The key blood levels for mitragynine are: all cases 
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(n = 71) - mean 0.853, range 0.00089 - 16.000 mg/L; with other substances (n = 62) - mean 0. 
0.8903, range 00089 - 16.000 mg/L; and as a sole drug (n = 3) - mean 0.398, range 0.0035 - 0.890 
mg/L. The post-mortem mitragynine blood levels for four of the UK cases are above the median levels 
previously reported in the literature for other cases, case 3 being the highest level yet reported. The 
blood level for 7-hydroxymitragynine is only known for 5 cases - mean 0.66218, range 0.0009 - 2.8 
mg/L. The 7-hydroxymitragynine levels for three UK cases (0.17, 0.19 and 2.8 mg/L) were all higher 
than the sole one (0.15 mg/L) previously reported in the literature (Karinen et al., 2014). 
 
< Tables 2a and 2b about here > 
 
In only six of all reported cases with toxicology information available (n = 129) was mitragynine the 
sole substance identified in the post-mortem toxicology; the ratio of mitragynine as sole mention to 
any mention in toxicology is 0.0465:1.0000. However, mitragynine was the sole drug implicated in 27 
out of 117 cases where the cause of death is known (Table 3); the ratio of mitragynine as sole 
mention to any mention in the cause of death is 0.231:1.000. Six of these 27 cases are the same 
cases where mitragynine was the sole drug detected in toxicology; a ratio of 0.222:1.000. Mitragynine 
was detected in all but one case, i.e. in 155 cases. Of these, levels are available for 71 cases (45.8%) 
but unavailable/not given for 84 cases (54.2%). Mitragynine was mentioned in the cause of death for 
85 (54.87%) of the 155 cases where it was detected. The substance was mentioned in the cause of 
death in 39/71 (54.9%) cases where levels were also stated. 
 
The main classes of other substances found can be broadly grouped into three categories: 
controlled/recreational drugs; therapeutic drug classes; and alcohol. Of importance is the fact that 
many drugs identified in these cases are Central Nervous System (CNS) depressants; particularly O-
desmethyltramdol, other opiates/opioids, benzodiazepines and alcohol. Stimulants and therapeutic 
drugs used to treat anxiety, depression and psychoses were commonly found. NPS including 
‘designer benzodiazepines’, ‘designer opioids’, and synthetic cathinones, have also been recently 
reported in combination with kratom. Where known, poly-substance use was found in the majority 
(87.2%) of cases; the average in such cases being three or four (mean = 3.4, range 1 - 10) drugs in 
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addition to mitragynine/7-hydroxymitragynine. Often, combinations include opiate/opioid(s) and/or 
benzodiazepine(s) and/or anxiolytic(s)/anti-depressant(s)/anti-psychotic(s) and/or stimulant(s). 
 
< Table 3 about here > 
 
The main cause(s) of death and autopsy findings are presented in Table 4. The key issues emerging 
can be broadly categorised into five: (a) breathing difficulties, especially congested and/or 
oedematous lungs; (b) cardiac/cardio-respiratory issues; (c) brain damage/hypoxia; (d) toxic effects of 
kratom/Krypton (with other substances); and (e) liver/urinary problems. 
 
< Table 4 about here > 
 
The 27 deaths where the sole drug found reported in the post-mortem toxicology and/or implicated in 
deaths are summarised in Table 5. Of note in these cases are: all decedents are male and White 
(where ethnicity is known), with a mean age of 32 years. Where known, the majority are: employed, 
living with someone, and have a history of drug use, including kratom. 
 
< Table 5 about here > 
 
The mean blood level is about half that of all cases where levels are known, but there are only three 
cases where levels are available. In all cases, Mitragynine/Kratom toxicity, toxic effects, overdose or 
intoxication is specifically mentioned is the autopsy/cause of death. Common features are: pulmonary 
congestion and/or oedema, and other respiratory conditions; effects on the brain; cardiac/circulatory 
conditions/diseases; and liver conditions. Where manner of death is known, most deaths were 
regarded as accidental or misadventure. 
 
 
5. Discussion 
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As far as the authors are aware, this paper presents the most comprehensive summary of deaths (n = 
156) linked to kratom use yet published. Only 40 of these cases have been reported previously in the 
scientific literature.   
 
5.1. Trends in reporting kratom-related deaths 
 
The number of cases being reported since 2008, both in the scientific literature and the media more 
generally, has constantly grown. This increase in the number of deaths associated with kratom use 
may be due, in part, to cases being more liable to be reported due to increasing interest in its use by 
potential/actual users and by the media, and therefore more active surveillance, identification and 
official/scientific recording. This phenomenon was observed in the UK in relation to MDMA-related 
fatalities following the death of Leah Betts in 1994 (Schifano et al., 2006). 
 
It is likely that more reports will occur as individual European countries and states in the USA, and the 
Federal government, become aware of the potentially fatal consequences of taking kratom or 
synthetic compounds containing mitragynine and its metabolite 7-hydroxymitragynine and introduce 
controls on its availability. This aspect will be important to monitor, especially since the coming into 
force in the UK on 26 May 2016 of the Psychoactive Substances Act 2016 which appears to capture 
kratom’s psychoactive components, e.g. mitragynine and 7-hydroxymitragynine within its scope. The 
‘Krypton’-related deaths in Sweden, which also included O-desmethyltramadol in the product, led to 
this molecule becoming controlled in the UK (Home Office, 2013). 
 
Increasing reports of adverse effects and toxicity including deaths associated with the use of kratom 
or related products led to the US Drug Enforcement Agency (DEA) to announce on 31 August 2016 a 
proposal to add mitragynine and 7-Hydroxymitragynine temporarily to Schedule 1 of the 1970 
Controlled Substances Act (DEA, 2016a). This was met with many calls from interest groups for the 
DEA to reconsider its suggestion. Following much pressure, the DEA withdrew its Notice of Intent on 
13 October 2016 and opened a period of public consultation which finished on 1 December 2016 
(DEA, 2016c). The Agency’s consideration of representations is still awaited at the time of writing. At 
the time of writing, some 6 states in the US have banned kratom. 
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There are likely to be other cases which have either not been identified or not reported in the scientific 
literature yet. For example, there has been justified criticism that the details of cases cited by the DEA 
in support of its proposal to schedule kratom (DEA, 2016b) are either not given at all, or key 
information such as toxicological levels and other key aspects are not presented (see below). This 
information needs to be published whenever and wherever possible, allowing for suitable anonymity 
regarding the identity of decedents. 
 
Some claim that no deaths have occurred in South-East Asia (e.g. Singh et al., 2016), although some 
have been documented (e.g. Tungananuwat and Lawanprasert, 2010). However, it is very likely that 
other deaths have occurred or are occurring there and in other parts of the world where kratom is 
used as a self-medicating therapeutic agent to treat opiate/opioid dependence. There is a lack of 
information on drug-related poisoning deaths in Malaysia (Raj, 2017). For all the above-mentioned 
reasons, and probably others, such as poor identification, investigation and reporting of drug-related 
deaths in this region, deaths associated with kratom are likely to be unreported. 
 
To date, there is only a single case-report from Thailand (Tungtananuwat and Lawanprasert, 2010), 
although mitragynine was found in the systems of two homicide victims in central Bangkok in the 
period 2009-2103 (Sakulsaengprapha et al., 2018). The presence of mitragynine is not a surprise, 
given its widespread use in Thailand. 
 
There is a lack of detailed published information on mortality statistics in Thailand, making it 
impossible to know what the true nature and extent of kratom-related deaths are in that country 
(personal communication to lead author from Kanlayarat Karnman, 24 June 2018). The same 
situation would appear to hold in Malaysia and Vietnam. Even in the UK and USA there are no 
accurate published national figures available. 
 
5.2. Demographics of those dying 
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The cases described here share many characteristics in common with the other cases so far 
described in academic literature, government reports and media reports. A typical decedent is White, 
male, aged in their early 30s, employed and lived with someone else.  
 
The reasons for using kratom, the use of additional substances, including CNS depressants, cause of 
death/autopsy findings and nature of death reflect the other cases reported. Self-medication emerged 
as the main reason for taking kratom, especially in connection with opiate/opioid use. Such use is 
common in Thailand and Malaysia (Cinosi et al., 2015), and appears to be spreading to Western 
countries (Smith and Lawson, 2017). However, its use as a recreational drug is somewhat limited; for 
example, it does not appear to be used be in the clubbing or music scenes (Martinotti et al., 2017; 
Santacroce et al., 2017).  
 
What is new in these cases is its link to body-building and to avoid positive opiate/opioid drug tests (at 
work or whilst in a drug rehabilitation programme). The type(s) of kratom products and the leaves 
from which they have been produced are not well reported. Where such information was given in the 
case reports reviewed here, it would appear that the most common products were used for 
relaxing/pain relief and euphoric/energising effects, often in combination.  
 
Kratom has been added as an ingredient in an energy drink promoted at large sports gatherings. 
Mitragynine’s role as a performance-enhancing substance was added to the repertoire to be screened 
for at sporting events (Guddat et al., 2016), and was added to the World Anti-Doping Agency’s 
(WADA’s) 2016 Monitoring Program in January 2016 (WADA, 2015). By the end of 2017, neither 
kratom nor mitragynine were listed in WADA’s Anti-Doping Testing Figures Reports 
(https://www.wada-ama.org/en/resources/laboratories/anti-doping-testing-figures-report). 
 
5.3. Toxicological analyses 
 
Mitragynine and its metabolites are unlikely to be included in standard toxicology screens or routine 
drug testing (Philipp et al., 2011); although increasing awareness of the use of kratom and its 
products may alter this situation. Tests for kratom-derived compounds are not widely available 
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(Philipp et al., 2011). Most toxicology laboratories need to send their samples to specialist 
laboratories for identification and quantification of mitragynine and 7-hydroxymitragynine (Anderson et 
al., 2014; Streete, 2014). There are difficulties in obtaining reference samples for analysis (Holler et 
al., 2011). It may be necessary to replenish purchased reference samples of mitragynine standard 
solution in methanol on a regular basis, even though stored as recommended. This can be expensive. 
 
In the UK context, Mitragynine and/or its metabolites were detected in using a Basic Drugs Screen in 
GC/MS and the presence and quantification of mitragynine and 7-hydroxymitragynine confirmed by 
LC-MS/MS. One of the authors estimates that the limit of detection for mitragynine on the GCMS is 
between 0.1 and 0.2 mg/L with their system/extraction technique. 
 
According to the standard reference work, Baselt et al. (2017), the highest recorded post-mortem 
blood level for mitragynine is 1060 μg/L and a urine level of 3470 μg/L. there are no levels given for 7-
Hydroxymitragynine. Taking into account all the cases presented here with levels, the mean post-
mortem blood level for mitragynine is 0.775 (range 0.00089 – 16.000) mg/L; the mean urine level is 
1.090 (range < 0.010 – 3.470) mg/L. For 7-Hydroxymitragynine the respective mean blood and urine 
levels are 0.66218 (range 0.0009 - 2.8) mg/L and 2.20 mg/L.; however, very few levels are available 
for this metabolite. Where only kratom was implicated in death and/or the only substance found in 
post-mortem blood samples (n = 3) the following levels have been reported: mean 0.398 (range 
0.0035 – 0.890) mg/L. 
 
There is a lack of detailed reports giving levels of mitragynine and 7-hydroxymitragynine, especially 
the latter, in poisoning intoxications and fatalities (Karinen et al., 2014; Neerman et al., 2013; 
Tungtananuwat and Lawanprasert, 2010), as well as established dosages leading to such events 
(Brown et al., 2017), as well as safe ceiling doses for chronic consumption in humans (Kruegel and 
Grundmann, 2018). Indeed, three of the known cases where 7-hydroxymitragynine levels are known 
were analysed by one of the present authors. Testing for 7-hydroxymitragynine testing is imperative, 
as it is typically not detectable in raw leaf consumption. Levels of mitragynine appear to be increasing, 
and when we see these increased levels, one could speculate that having detectable levels of 7-
hydroxymitragynine could indicate a trend in consumption of extracted and/or artificially enhanced 
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products. Therefore, testing for, and detection of, quantifiable levels of 7-hydroxymitragynine would be 
helpful in checking out this theory. Brower (2015) suggests that the hydroxy metabolite could be 
identified via an organic bases screen; it elutes just before trazodone. One of the authors found that 
the metabolite elutes 0.4 min before mitragynine. It can be quantitated via LC/MS. Chromatography is 
also important in screening for the metabolite.  
 
There is only a single case-report on driving under the influence of kratom (Wright, 2018); however, 
mitragynine was only qualitatively detected. Variations in the concentrations and potencies of different 
strains of kratom and derivatives, as well as inter-individual differences in pharmacokinetics may also 
be relevant factors to consider. Therefore, the publication of additional details will be of assistance to 
those investigating deaths where kratom was consumed. Without such information it is very difficult to 
define what constitute toxic/fatal doses and post-mortem levels/concentrations, especially as there is 
a dearth of cases where only mitragynine and/or 7-hydroxymitragynine are identified. A balanced 
approach to presenting information, whether based on quantitative sources or anecdotal evidence, is 
required, especially in relation to reporting adverse consequences associated with kratom use, as 
anecdotal evidence can weigh more heavily in affecting such choices (Gutierrez and Cohn, 2018). 
 
5.4. Cause/mechanism of death 
 
The leading issue identified from autopsy reports is that of congested and/or oedematous lungs 
(Table 4). However, such findings are very common in a high percentage of all autopsy reports. On its 
own, without histology and/or toxicology to confirm a kratom-related pathology, such a finding is 
inconclusive with respect to kratom causing death. Brain damage, principally due to hypoxia, is often 
seen in the cases described here, but this should be expected when deaths have occurred when 
there has been cardio-respiratory depression, the inhalation of gases, asphyxiation (including 
hanging), etc.  
 
Cardiac issues also appear to be one of the key mechanisms of/contributions to death. In some 
cases, these appear to be already known as part of a decedent’s medical history, or in some 
instances undiagnosed and/or triggered by the consumption of a psychoactive substance, especially 
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stimulants. The use of substances in this latter category appears to have been common, as reflected 
in prevalence surveys, as does their involvement in the cause of death (see below). Liver and urinary 
issues are also mentioned in the cases investigated here; for some, these conditions appear to have 
been chronic. However, there may be a higher incidence of such findings if the autopsy results for all 
cases were to be made available. 
 
An awareness of the potential contribution that underlying medical conditions, especially undiagnosed 
ones, may make to the risk of death is important to convey to (potential) kratom users and those 
treating suspected kratom overdoses/intoxications. The principal concern here would appear be that 
of cardiac problems, especially cardiomegaly, coronary atherosclerosis and left ventricular 
hypertrophy (Table 4). Those with enlarged livers may also be at greater risk. 
 
As with the recording and reporting of most drug-related poisoning fatalities, the actual mechanisms 
of death are poorly described in the cause of death fields on medical certificates of death; as indeed, 
are details of the substances themselves (Fugelstad et al., 2018; Jones and McAninch, 2015; Shai, 
1994; Slavova et al., 2015).  
 
This is not peculiar to any one country or geographical region of the world; and it undermines the 
accurate attribution of the initial underlying incident and the actual sequence of events and processes 
culminating in death itself, and thus accurate mortality statistics (Corkery, 2008; Shai, 1994). This 
issue has been known about for decades, especially amongst those responsible for instructing 
doctors and others completing death certificates, e.g. medical schools (Corkery, 2008; Shai, 1994). 
Yet, it still exists! In the UK, moves are afoot to try and mitigate these shortcomings. From April 2019 
medical examiners will start checking all death certificates issued by treating doctors for accuracy and 
compliance with coroner notification obligations (DHSC, 2018; Luce and Smith, 2018). 
 
5.5. Manner of death 
 
Where known, the majority of deaths were ‘accidental’ in manner (93/131; 71%), including 
‘misadventure’ cases (Table 1); for some coroners this implies that the decedent is aware that drug-
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taking may involve some degree of risk-taking, for others there is no distinction between that and an 
‘accident’ in the common-sense meaning of that term. About 9% of deaths were ‘intentional’, 
predominantly suicide, although there was one homicide. Some of the ‘intentional’ cases could be 
construed as being akin to the ‘misadventure’ category, whilst others where an ‘open’ or 
‘undetermined’ finding was returned may be possible suicides. This spread of conclusions is broadly 
consistent with UK findings for drug-related deaths as a whole. 
 
5.6. Consumption of kratom and contribution to death 
 
The adverse, intoxicating, toxic or poisoning effects of kratom and/or other substances is the 
dominant theme emerging from the cause of death information provided (103/117; 88%). 
 
In 27 cases reported here, where information was available on the cause of death (n = 117), kratom 
alone was implicated in the cause of death used/found on its own. In six of these case reports 
mitragynine and/or 7-hydroxymitragynine was the sole substance found in the toxicology. An overview 
of these 27 cases is given in Table 5. The key characteristics of the individuals who died are similar to 
those for all the deaths reported here: male; White; mean age of 32 years; employed; living with 
someone; and have a history of drug use, including kratom. The principal characteristics of the deaths 
themselves are: taking place at home address; resulting from intoxication, toxic effects, or overdose; 
accidental in manner; exhibiting pulmonary and/or cerebral congestion/oedema, cardiac and hepatic 
problems.  
 
The majority of deaths reported here involved poly-substance consumption. This echoes the patterns 
observed in online fora with regard to usage (Cinosi et al., 2015). As mitragynine and its main 
metabolite 7-hydroxymitragynine bind to the µ and δ receptors causing an opioid-like effect at high 
doses and a stimulant-like effect at low doses, it is likely that they potentiate the effects of other 
substances consumed. The combination of kratom and stimulants (including NPS) could contribute to 
causing cardiac problems, whilst its use with CNS depressants (such as opioids, benzodiazepines, 
and alcohol mentioned in the cases reviewed here) clearly could cause potentially fatal cardio-
respiratory problems.  This likelihood is under-pinned by the fact that multi-substance use has been 
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associated with a greater risk of admission to a health care facility and/or a serious medical outcome 
(Post et al., 2019). The corollary is that using kratom on its own is likely to be safer than using it in 
combination with alcohol and/or other drugs; but underlying health conditions may still be relevant in 
terms of risk of dying. As mitragynine appears to have a lower lethality index than heroin (King and 
Corkery, 2018), its use in self-medicating for opiate/opioid dependence in countries where it is grown 
and produced could be seen as a de facto harm reduction activity. 
 
The possibility of kratom-prescribed medication interactions is raised in some cases. For example, 
quetiapine’s metabolism and clearance may be affected by mitragynine, possibly via its inhibitory 
effects on CYP2D6, CYP2C9 and other enzymes (Hughes, 2019). Sertraline also appears to be 
potentially affected in this way as it is metabolised via CYP2D6 (Hanapi et al., 2013). 
 
5.7. ‘At-risk’ groups 
 
The information for all cases collated in this study (see Tables 1 to 4) suggests the possibility of seven 
categories of kratom users at greater risk of dying, some of which overlap: 
 
(a) those using kratom in the context of opioid use, especially heroin, fentanyl and morphine, novel 
opioids (such as fentanyls, U-47700), e.g. for chronic pain relief; 
(b) those using kratom in the context of benzodiazepine use, including ‘designer benzos’ (such as 
etizolam);  
(c) those using kratom in the context of multiple CNS depressant drugs, especially opioids and 
benzodiazepines (with or without alcohol);  
(d) those consuming kratom in the context of recreational drug use, including stimulants 
(amphetamine/methamphetamine, ecstasy, cocaine), and NPS;  
(e) those with cardiovascular and/or hepatic medical conditions (whether diagnosed or undiagnosed), 
especially where stimulants are used;  
(f) those with psychiatric or mental health issues, such as anxiety and depression, including those 
taking prescribed psychiatric medicines (such as quetiapine or sertraline); and 
(g) those taking prescribed anti-epileptics, gabapentinoids. 
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A limitation of this profile of users is that it is based on deaths covered by this study; many of which 
have limited demographic information. However, the period is sufficiently long to see the impact of 
emerging novel psychoactive substances, especially opioids (Schifano et al., 2015). 
 
5.8. Strengths and limitations of this study 
 
This is the first study to draw together information on UK kratom-related fatalities. It also presents the 
first comprehensive international overview and detailed analysis of cases in the public domain at the 
time of writing. Although most of the data are from the USA and Europe, it provides a robust dataset 
of nearly 160 cases from which more reliable conclusions can be drawn than hitherto. The key 
findings presented here echo those in a recent summary of 152 US fatalities positive for post-mortem 
mitragynine during July 2016-December 2017 (O’Malley Olsen et al., 2019); some of those cases may 
be included in our present study.  
 
This study has, out of necessity, drawn on a wide range of data sources to collate information on as 
many kratom-related fatalities as possible, thereby facilitating the provision of a dataset that can be 
objectively analysed and appropriate scientific conclusions made. The quality of the data and their 
sources vary considerably, but the inclusion of less robust sources is justified in our opinion, as was 
done in studies looking at khat-related fatalities (Corkery, 2011; Corkery et al., 2011a, 2011b). 
 
In terms of a hierarchy of evidence, the present investigation and similar studies probably lie towards 
the bottom of the evidential pyramid. For example, using a simple 4-tier approach: level 1 – 
generalisable studies; level 2 – conceptual studies; level 3 – descriptive studies; level 4 – single case 
study (Daly et al., 2007), some of the data used here come from levels 3 and 4. In a broader range of 
levels: Metanalysis; Systematic Reviews; Randomised Controlled Clinical Trials; Cohort studies; 
Case-Control Studies; Case Series/Case Reports; Editorials and Expert Opinions; in vivo studies; in 
vitro research studies, proposed by Sayre et al. (2017), the data employed in the present study come 
from levels straddling the middle of this continuum. It thereby demonstrates the need to be pragmatic 
in selecting approaches to research under-explored phenomena such as kratom-related fatalities. An 
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improved database of properly collated data, as advocated above, would help in making future 
studies on such deaths appear higher up the evidential pyramid.  
 
The specific types of sources are listed against each case in the supplementary table, together with 
an indication of their completeness. The level of evidence for a specific case in the present study in 
descending order are: (a) documents relating to the incident investigation, the autopsy report and 
toxicology report; (b) documents relating to the incident investigation together with the autopsy report 
incorporating the main toxicological results; (c) summary by the coroner/medical examiner/chief 
investigator; (d) FDA Adverse Event Reporting System (FAERS) report; (e) published case-study; (f) 
published case-series; (g) media report. That said, there is some variability in the quality in terms of 
completeness and consistency of sources within these categories, especially the data published by 
the FDA. 
 
The documents published by the FDA (2018a, 2018b, 2018c) in support of its case to include kratom 
into Schedule 1 of the Controlled Substances Act 1970 largely come from the FAERS. This contains 
entries: (a) relating to published academic papers, including many of those included in this analysis; 
(b) summaries of investigations by police, coroners and medical examiners that include details of 
autopsy and toxicology reports; as well as (c) very brief and uninformative anecdotal reports. Similar 
observations could be made in regard to the DEA’s Three Factor Analysis (DEA, 2016b).  
 
There is a need for measured and accurate reporting. For example, even the National Institute on 
Drug Abuse (NIDA) has unhelpfully concluded that “Most kratom associated deaths appear to have 
resulted from adulterated products (other drugs mixed in with the kratom) or taking kratom along with 
other potent substances (sic) …” (NIDA, 2019). Whilst the second clause is quite correct, the initial 
part of this sentence is very misleading. Such wording only serves to obfuscate scientific debate and 
progress.  
 
The media, interest groups, and policy-makers as well as scientists need to be as accurate as 
possible in presenting information and making inferences, which should be evidence-based. This can 
only be done through comprehensive screening and identification of cases, proper collection and 
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accurate collation of data, especially toxicology levels, known medical history, concomitant use of 
other substances, and objective dissemination of information regarding deaths associated with kratom 
use. The exact nature of such links, if any, in terms of causality or contribution to deaths, including 
any caveats about interpretation, should be explicit. To do otherwise creates difficulties for 
investigating and understanding the epidemiology of such cases, and their future prevention. To 
mitigate such issues in the present paper, attempts were made to obtain copies/sight of autopsy and 
toxicology reports as well as police investigation reports. 
 
Additional limitations of this paper need to be noted. Further details of cases reported in the media 
and conference abstracts need to be obtained to fill out the data for the cases presented here. Not all 
cases have been necessarily identified. However, this is believed to be the first paper where a 
systematic analysis of reported cases has been conducted. 
 
 
6. Conclusions 
 
The findings presented here add to the existing knowledge-base on deaths associated with kratom 
use. This paper confirms that a growing number of such fatalities is being reported, and it identifies 
that in most cases this is in association with the abuse of other psychoactive substances. Typically, 
CNS depressants including opiates/opioids, benzodiazepines and alcohol are found at post-mortem, 
along with recreational drugs such as controlled stimulants and ‘legal highs’/NPS, as well as 
prescribed therapeutic medications. As noted earlier, kratom was the sole drug implicated in 23.1% of 
cases examined here where the cause of death is known. Although the mortality data used by King 
and Corkery (2018) relate to England and Wales, applying their method of sole to any mention of an 
index in the cause of death, it would appear that kratom (mitragynine) has a higher lethality index than 
novel amphetamines, benzodiazepine analogues, cannabis, piperazines, and synthetic cathinones, 
but one that is lower than amphetamines, benzofurans, cocaine/crack, and other more potent 
substances. Underlying medical conditions, both already diagnosed or suspected as well as unknown 
at the time of death, can contribute to the way in which kratom takes or effect and vice versa. These 
findings support the emerging literature about the plant. 
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These facts need to be taken into account by: current and potential consumers of kratom; health 
professionals when faced with acute/chronic presentations in hospitals; and those engaged in 
planning prevention and treatment services. There is a need to educate health professionals, 
including clinicians, pathologists and medical examiners, as well as making psychiatrists and sports 
scientists aware of the different ways in which the plant is used. 
 
The safety profile of Mitragynine speciosa still remains only partially understood, despite its increasing 
popularity. Further research is needed in respect of kratom on: deaths in South-East Asia where 
kratom is widely used; the levels of mitragynine and its metabolites consumed and possible 
interactions with other substances; toxic and fatal levels. 
 
Above all, this study has demonstrated that without reliable, accurate and complete information that is 
correctly collated, scientifically analysed and disseminated in a timely manner, the phenomenon of 
what deaths can be ascribed to the use of kratom and the nature of any association(s) that can be 
made will remain unrealised. 
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Figure 1: Chemical structure of mitragynine 
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Figure 2: Chemical structure of 7-mitragynine 
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Table 1: Summary of main characteristics of case-reports of deaths associated with 
Kratom/Krypton use 
 
Variable Characteristic Frequency 
Country of death Canada 
Germany 
Ireland 
Norway 
Sweden 
Thailand 
USA 
United Kingdom 
1 
2 
1 
1 
9 
1 
131 
10 
Year of death 2008 
2009 
2010 
2011 
2012 
2013 
2014 
2015 
2016 
2017 
2018 
Nov 2009 – Spring 2010 
Pre-Oct 2011 
Pre- Dec 2014 
2012-6 
Not known 
1 
3 
1 
0 
0 
6 
5 
17 
27 
43 
14 
8 
1 
1 
14 
15 
Year of first report 2008 
2009 
2010 
2011 
2012 
2013 
2014 
2015 
2016 
2017 
2018 
2019 
0 
1 
2 
10 
1 
1 
7 
17 
19 
35 
46 
17 
Gender Male 
Female 
Female (born male)/Transgender 
125 
30 
1 
Stated age (where known, n = 133) Min 
Max 
Average (mean) 
17 
64 
32.31 
Calculated age (where known, n = 55) Min 
Max 
Average (mean) 
20.87 
64.26 
33.98 
Ethnicity  Caucasian 
White 
White, non-Hispanic 
White, non-Latino 
White, Hispanic 
White, Latino 
Not known 
5 
61 
15 
7 
1 
2 
65 
Employment status (where known, n = 42) 
 
Unemployed/ receiving social benefits 
Student 
Volunteer/retired 
Employed 
6 
7 
1 
28 
Living arrangements (where known, n = 44) Alone 
With parent(s) 
With son/daughter 
With family 
With partner 
With friend/room-mate 
In prison 
In drug treatment centre 
8 
12 
1 
12 
5 
4 
1 
1 
Drug use (where known, n = 86) No previous known drug use 
History of drug use 
Previous use of Kratom/Krypton 
4 
82 
27 
74 
 
Reasons for using kratom (where known, n = 
26) – there may be more than one reason for 
an individual using kratom 
Body-building 
Recreational 
Self-medication 
   Anxiety/stress 
   Depression 
   Opiate/opioid addiction 
   Chronic pain relief 
   Insomnia 
   ADHD symptoms 
   Kratom dependence 
   Diarrhoea 
Avoid positive opiate/opioid drug test 
To relax 
Experimentation 
Supplement to provide energy and mood enhancer 
As a safe stimulant 
In an alternative treatment centre 
3 
3 
 
5 
1 
4 
3 
1 
1 
1 
1 
2 
2 
1 
1 
1 
2 
Place of death (where known, n = 112) 
 
Home 
Friend’s home 
Family member’s home 
Hostel 
Hotel/motel 
Living quarters 
Outside home address 
Hospital/medical centre 
Vehicle 
Drug treatment centre 
Alternative treatment centre 
Fuel/gas station 
Highway 
Lake 
Water treatment plant 
Rural location 
Open space 
Pig-sty 
Playing sports 
Work 
66 
6 
2 
1 
2 
1 
1 
15 
4 
2 
2 
1 
1 
1 
1 
1 
1 
1 
2 
1 
Nature of death – verdict/conclusion/manner  Accidental 
Accidental drug intoxication/overdose/poisoning 
Drug-related 
Drug and Alcohol related 
Misadventure 
Intentional 
Intentional – misuse of drugs 
Intention unclear 
Open verdict 
Suspected suicide 
Suicide 
Homicide 
Undetermined 
Natural 
Not known 
71 
19 
2 
3 
4 
2 
1 
1 
1 
2 
6 
1 
2 
1 
25 
N  156 
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Table 2a: Mitragynine and 7-hydroxymitragynine levels in human fatalities – individual cases 
 
Source Source case 
number 
Other 
substances 
present 
Mitragynine 7-hydroxymitragynine 
Holler et al., 2011 
[n = 11] 
 Y Heart [central] bl 0.39 mg/L 
Liver 0.12 mg/kg 
Kidney 0.16 mg/L 
Vitreous 0.15 mg/L 
Urine 1.20 mg/L 
 
Kronstrand et al., 
2011 
1 
2 
3 
4 
5 
6 
7 
8 
9 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Femoral bl 0.07 mg/L 
Femoral bl 0.16 mg/L 
Bl 0.04 mg/L 
Femoral bl 0.05 mg/L 
Femoral bl 0.18 mg/L 
Femoral bl 0.05 mg/L 
Femoral bl 0.03 mg/L 
Femoral bl 0.02 mg/L 
Femoral bl 0.05 mg/L 
 
Frost et al., 2012; 
Neerman et al., 2013 
 Y Femoral bl 0.60 mg/L  
Karinen et al., 2014  Y Femoral bl 1.06 mg/L 
Urine 3.47 mg/L 
Femoral bl 0.15 mg/L 
Urine 2.20 mg/L 
McIntyre et al., 2015  Y Peripheral bl 0.23 mg/L 
Central bl 0.19 mg/L 
Liver 0.43 mg/kg 
Vitreous <0.05 mg/L 
Urine 0.37 mg/L 
 
Brower, 2015 
(cases 3 and 4 are 
included below in 
Bishop-Freeman et 
al., 2016) 
1 
2 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
NK 
NK 
Y 
Y 
Y 
Y 
Y 
NK 
Y 
Y 
NK 
NK 
Y 
Bl 0.42 mg/L; liver >8.0 mg/kg 
Bl 2.0 mg/L; liver >8.0 mg/kg 
Bl 0.18 mg/L; liver 0.71 mg/kg 
Bl 0.35 mg/L; liver 0.48 mg/kg 
Bl 0.88 mg/L; liver 3.8 mg/kg 
Bl 0.075mg/L 
Bl < 0.050 mg/L 
Bl 0.36 mg/L; liver 3.3 mg/kg 
Bl 0.21 mg/L; liver 0.60 mg/kg 
Bl 0.031 mg/L 
Bl 1.1 mg/L; liver 6.2 mg/kg 
Bl 0.30 mg/L; liver 1.4 mg/kg 
Bl 2.0 mg/L; liver > 8.0 mg/kg 
 
Brower et al., 2015   Peripheral [femoral?] bl 
median 0.27, range 0.021-3.8 
mg/L (n=8) 
Central [heart] bl median 
0.60, range 0.60-0.60 mg/L 
(n=2) 
Liver 1.8 range 0.48-3.8 
mg/kg (n=5) 
Vitreous 0.16 mg/L (n=1) 
Urine 0.92, range 0.05-1.8 
mg/L (n=2) 
 
Bishop-Freeman et 
al., 2016 
12 
19 
 
20 
Y 
Y 
 
Y 
Peripheral bl < 0.050 mg/L 
Peripheral bl 0.60 mg/L 
Liver 0.68 mg/kg 
Liver 3.5 mg/kg  
 
Domingo et al., 2017 1 
 
2 
Y 
 
Y 
Femoral bl 0.790 mg/L 
Urine > 0.400 mg/L 
Femoral bl 0.010 mg/L 
Urine < 0.010 mg/L 
 
Ramoo et al., 2017 P. 187 Y Sub-clavian bl 980 ng/mL  
Fogarty et al., 2018 1 Y Iliac bl 0.890 ng/mL  
Wang and Walker, 
2018 
 Y Femoral venous bl 2500 
ng/mL 
 
Gershman et al., 
2019; 
5 
7 
8 
9 
10 
11 
12 
13 
14 
15 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
16 ng/mL 
140 ng/mL 
2100 ng/mL 
1400 ng/mL 
1000 ng/mL 
170 ng/mL 
2700 ng/mL 
4800 ng/mL 
250 ng/mL 
747 ng /mL 
 
76 
 
Additional cases 
from current study 
2 
3 
4 
5 
7 
35 
36 
37 
47 
48 
50 
52 
53 
54 
55 
56 
 
60 
67 
68 
69 
87 
88 
89 
93 
100 
101 
102 
103 
104 
111 
138 
140 
Y 
Y 
Y 
Y 
Y 
N 
Y 
Y 
N 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
 
Y 
Y 
Y 
NK 
Y 
N 
Y 
Y 
Y 
Y 
Y 
Y 
Y 
N 
Y 
Y 
Fem bl 1.6 mg/L 
Fem bl 16.0 mg/L 
Fem bl 2.3 mg/L 
Fem bl 0.42 mg/L 
Bl 0.051 mg/L 
Liver - 86mg/Kg 
Peripheral bl 1.7 mg/L 
Peripheral bl 0.50 mg/L 
Bl 3500 ng/mL 
Peripheral bl 1.8 mg/L 
Bl - 920 ng/mL 
Peripheral bl 0.13 mg/L 
Peripheral bl 0.50 mg/L 
Peripheral bl 1.7 mg/L   
Peripheral bl 0.68 mg/L  
Peripheral bl 0.68 mg/L; liver 
0.51 mg/kg 
Femoral bl 92 ng/mL 
Peripheral bl - 0.74 mg/L 
Peripheral bl - 0.46 mg/L 
Serum 4200 ng/mL 
Bl - 40 ng/mL 
Iliac bl - 300 ng/mL 
Bl - 24 ng/mL 
6.2 mg/kg 
Chest fluid - 13 ng/mL 
AM peripheral bl 1600 ng/mL 
290 ng/mL 
Bl - 720 ng/mL 
Femoral bl - 830ng/mL 
Bl - 890 ng/mL 
Iliac bl 2300 ng/mL 
Bl – 0.15 mg/L 
Bl 0.19 mg/L 
Bl 2.8 mg/L 
Fem bl 0.17 mg/L 
 
Bl 0.0009 mg/L 
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Table 2b: Mitragynine and 7-hydroxymitragynine levels in human fatalities 
 
Mitragynine 
 
Blood:  
All cases 
Mean 0.853, range 0.00089 
– 16.000 mg/L (n=71) 
Sole drug  
Mean 0.398, range 0.0035 – 
0.890 mg/L (n=3) 
With other substances 
Mean 0.8903, range 0.00089 
– 16.000 mg/L (n=62) 
Presence of other drugs 
unknown 
Mean 0.697, range 0.0042 - 
2.000 mg/L (n=6) 
 
Liver: 
All cases 
Mean 8.233, range 0.120 – 
86.000 mg/kg (n=16) 
Sole drug  
86 mg/kg (n=1) 
With other substances 
Mean 1.883, range 0.120 - > 
8.000 mg/kg (n=10) 
Presence of other drug 
unknown 
Mean 5.380, range 1.400 - > 
8.000 mg/kg (n=5) 
 
Urine: 
With other substances 
Mean 1.090, range < 0.010 – 
3.470 mg/L (n=5) 
 
Vitreous humour: 
With other substances 
Mean 0.100, range < 0.050 – 
0.150 mg/L (n=2) 
 
Kidney: 
With other substances 
0.160 mg/L (n=1) 
7-hydroxymitragynine 
 
Blood:  
Mean 0.66218, range 0.0009 - 
2.8 mg/L (n=5) 
 
Urine:  
2.20 mg/L (n= 1) 
 
All cases had other 
substances present 
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Table 3: Main classes of other substances noted in post-mortem toxicology and cause of 
death for human fatalities associated with Kratom/Krypton use 
 
Class of substance Frequency 
 Toxicology Cause of death 
Only mitragynine/7-hydroxymitragynine 6 26 
‘Legal high’/NPS 25 13 
   of which, Synthetic opioid (5 U-47700; 12 novel fentanyls) 18 12 
                   Synthetic cathinone (4 bupropion) 5 1 
                   Benzodiazepine 8 2 
                   PCP-like 1 0 
Stimulant (e.g. cocaine, MDMA, etc.)  25 11 
   of which, Amphetamine/Methamphetamine 9 3 
                  Cocaine 10 5 
                  MDMA, MDA, ephedrine, pseudoephedrine 7 4 
                  DMAA 1 0 
                  2,4,5 TMA 1 0 
THC/cannabis/cannabinoid 11 0 
GHB 1 1 
Anxiolytic 18 4 
Anti-depressant (excluding benzodiazepine) 15 3 
Anti-epileptic (excluding gabapentin, pregabalin) 9 1 
Gabapentinoid 13 6 
Anti-histamine 21 10 
Anti-psychotic 16 2 
Benzodiazepine 50 18 
Any opiate/opioid 77 44 
O-Desmethyltramadol (9 Krypton cases) 10 1 
Heroin 21 12 
Fentanyl 22 16 
Morphine 13 8 
Codeine 8 7 
Tramadol 6 1 
Methadone 3 2 
Other opiates/opioids 24 11 
Non-opioid pain-killer 8 1 
Loperamide 5 0 
Dextromethorphan 4 1 
Muscle relaxant 3 1 
Alcohol 22 8 
Caffeine 12 0 
Helium 0 2 
Inhalant 2 0 
Naloxone 2 0 
Other 15 1 
Multiple substances 1 8 
Not stated/unascertained 19 53 
No Kratom/Mitragynine 1 1 
Notes Rows may sum to more than the total as more than one class of substance may have been identified; the true 
number of specific substances implicated in the cause of death may be higher as they have been included in cases 
involving “multiple drugs”, etc. 
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Table 4: Main causes of death/autopsy findings in fatalities associated with Kratom/Krypton 
use 
 
Cause of death/autopsy findings Frequency 
 Role of Kratom 
unclear 
Kratom only Combination of 
substances 
Total 
Head     
Cerebral oedema 6  7 13 
[Anoxic/Hypoxic] brain injury 1 1 1 3 
Hypoxic encephalopathy  3 1 4 
Infarct cranial pressure   2 2 
     
Heart & circulatory system     
Cardiac arrythmia   1 1 
Cardiomegaly 3  5 8 
Cardiomyopathy   1 1 
Coronary atherosclerosis  2 5 7 
Focal band necrosis in myocardium   1 1 
Heart attack 1 1  2 
Heart condition  1  1 
Hypertensive cardiovascular disease  2 1 3 
Left ventricular hypertrophy  3 3 6 
Myocardial ischaemia 1   1 
Myocarditis   1 1 
     
Respiratory system     
Adult Respiratory Distress Syndrome 1   1 
Aspiration of gastric contents 1 2 1 4 
Bronchopneumonia 1  2 3 
Cardio-respiratory failure/arrest  1 1 2 
Central Nervous System depression   2 2 
Central Nervous System & respiratory depression 1  1 2 
Chronic Obstructive Pulmonary Disease   1 1 
Congested and/or oedematous/ heavy wet lungs 6 5 15 26 
Congested larynx, trachea & bronchi 1 1  2 
Influenza pneumonia  1  1 
Pulmonary oedema 5 5 6 16 
Pulmonary thrombo-emboli   1 1 
     
Intoxication/overdose/toxicity     
Kratom overdose/toxicity, toxic effects of 
mitragynine/7-hydroxymitragynine 
 27  27 
Multidrug intoxication/toxicity   62 62 
Additive/combined/synergistic effect of drugs   4 4 
Polypharmacy overdose   1 1 
Combined adverse effects of drugs   1 1 
Poisoning 8   8 
Alcoholism  1 1 2 
     
Hepato/Renal/Urinary system     
Congested kidney 1   1 
Congested liver 1 1 1 3 
Distended bladder/urinary retention  1 3 4 
Enlarged liver/hepatomegaly 1 1 1 3 
Fatty change in liver/Liver steatosis 2 1 2 5 
Kidney stones  1  1 
Nephritis 1   1 
Liver fibrosis 1   1 
     
Trauma     
Asphyxia (hanging/mechanical) 1  2 3 
Blunt force head trauma, broken ribs 1   1 
Drowning 2   2 
Firearm discharge, intraoral => head defect 1   1 
Gunshot wound 1   1 
Gunshot wound to head 1   1 
Haematoma & fracture of left humerus   1 1 
Multiple injuries 1    
Plastic bag asphyxia with helium gas inhalation 2   2 
Thermal injuries, inhalation of products of combustion 1   1 
     
Other     
Deep vein thrombosis   1 1 
Diabetic ketosis   1 1 
80 
 
Epilepsy   1 1 
Metastatic breast carcinoma   1 1 
Obesity   1 1 
Oedema in lower extremities   2 2 
Seizures  1  1 
Thyroid disease  1  1 
     
Neither autopsy nor cause of death stated 24   24 
     
Note: More than one cause can be relevant to an individual case. 
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Table 5: Cases involving Mitragynine/7-Hydroxymitragynine/Kratom alone in cause of death 
 
Key characteristic Number (n = 27) 
  
Decedents  
Male 27 (100.0%) 
Age at death (years) Mean = 32.16; Range = 17 - 64 
Ethnicity Caucasian/White/White Hispanic = 20 (74.1%); Not known =7 (25.9%) 
Employment status Employed = 6 (22.2%); Unemployed, student, retired, on benefits = 3 (11.1%); Not 
known = 18 (66.7%) 
Living arrangements With someone = 7 (25.9%); Alone/in treatment centre/prison = 5 (18.5%); Not 
known = 15 (55.6%) 
History of drug use Yes = 18 (66.7%); No = 1 (3.7%); Not known = 8 (29.6%) 
Known to have previously used 
kratom 
Yes = 13 (48.1%); Not known = 14 (51.9%) 
Place of death At home = 16 (59.3%); Hospital/medical centre = 4 (14.8%); Alternative health/ 
treatment centre = 2 (7.4%); Not known = 5 (18.5%) 
Deaths  
Mitragynine blood level Mean 2.128 (range 0.016 – 16.000) mg/L (n=15) 
Main autopsy findings/cause of 
death 
 
Cerebral oedema = 2; Hypoxic encephalopathy = 2; Seizures = 2; Anoxic brain 
injury = 1;  
Underlying heart condition = 1; Atherosclerosis = 1; Severe atherosclerosis = 1; 
Cardiomegaly = 1; Left ventricular hypertrophy = 3; Hypertensive cardiovascular 
disease = 1; Cardio-respiratory arrest = 2; 
Pulmonary oedema/congestion = 9; Pulmonary emboli = 1; Congested larynx, 
trachea & bronchi = 1; Aspiration of gastric contents = 2; Haemophilus influenzae 
& Haemophilus parainfluenzae pneumonia = 1; 
Enlarged liver = 1; Fatty change of liver = 2; Congested liver = 1; Renal calculi = 1; 
Distended bladder = 1; 
Thyroid disease = 1; 
Ulcerative colitis = 1; 
Chronic alcoholism = 1;  
Mitragynine/Kratom toxicity/toxic effects = 18; Mitragynine/Kratom intoxication = 6; 
Kratom overdose = 2; Combined effects of Mitragynine & 7-Hydroxymitragynine = 
1 
Nature of death Accidental = 18 (66.7%); Misadventure = 2 (7.4%); Undetermined = 1 (3.7%); Not 
known = 6 (22.2%) 
 
